Anti-RSV (Palivizumab), Humanized Antibody

Anti-RSV (Palivizumab), Humanized Antibodyis available at Gentaur for Next week Delivery.

Description: The research-grade biosimilar is a humanized IgG1 kappa monoclonal antibody that is produced by recombinant DNA technology. The antibody is used to prevent RSV infections. RSV is a non-segmented, enveloped, single-stranded, negative-sense virus that is known to cause mild lower respiratory tract infections in infants. The antibody specifically targets an epitope in the antigenic A site (between amino acids 258 and 275) of the RSV fusion glycoprotein and prevents the entry of the virus inside the host cell. The antibody is composed of 95% human and 5% murine antibody sequences. It is consists of two heavy chains and two light chains and has a molecular weight of 148 kDa. The original drug received FDA approval to treat prophylaxis in children. It is also recommended to infants who are at high risk, either due to premature birth, or medical problems such as congenital heart disease and bronchopulmonary dysplasia (BPD).

Immunogen Sequence:Human RSV

Target Alternative Name:Human Respiratory Syncytical Virus, HRSV, MEDI 493, MEDI-493

Species Reactivities:Human

Tag Line:The biosimilar is a humanized monoclonal antibody that targets the fusion glycoprotein of the respiratory syncytial virus (RSV) and prevents the binding and uptake by the host cellular receptors

Formulation:In PBS, pH 7.5

Purification: Protein A purified

Application:/

Positive Control:/

Application And Usages:/

Handling:The antibody solution should be gently mixed before use.